About Clarus Therapeutics
Partnering and Licensing
Investors and Media
Phase 3 Trials
JATENZO® has been evaluated in three Phase 3 clinical trials which achieved their primary efficacy endpoint, namely restoration of serum T to the normal range.
© 2019 Clarus Therapeutics. All rights reserved.